https://www.evrysdievents.com/
Evrydsi® (risdiplam) | Official site for educational community events
Find a community educational event to learn more about Evrysdi (risdiplam). In-person and online events to learn about Evrysdi from experts and people taking...
official siteeducational communityrisdiplamevents
https://www.business-standard.com/amp/markets/capital-market-news/natco-pharma-submits-anda-with-us-fda-for-risdiplam-124112100654_1.html
Natco Pharma submits ANDA with US FDA for Risdiplam | Capital Market News - Business Standard
Natco Pharma informed that it has submitted the abbreviated new drug application (ANDA) with the United States Food and Drug Administration (USFDA) for...
https://www.news-medical.net/news/20181003/Genentech-announces-clinical-data-from-studies-investigating-risdiplam-in-spinal-muscular-atrophy.aspx
Genentech announces clinical data from studies investigating risdiplam in spinal muscular atrophy
Jun 18, 2019 - Genentech, a member of the Roche Group, announced today interim clinical data from the dose-finding parts of the pivotal FIREFISH and SUNFISH studies...
clinical data
https://boris-portal.unibe.ch/entities/publication/69e92f57-fc5b-4f8f-ab40-29bf6b7a9134
Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls.
BACKGROUND Type 1 spinal muscular atrophy (SMA) is a progressive neuromuscular disease characterized by an onset at 6 months of age or younger, an inability to...
spinal muscular atrophy
https://adisinsight.springer.com/patents/800044154
Risdiplam - PTC Therapeutics/Roche - AdisInsight
ptc therapeuticsrisdiplamrocheadisinsight
https://www.evrysdi-hcp.com/
Evrysdi® (risdiplam), An Approved Pediatric & Adult Spinal Muscular Atrophy (SMA) Treatment |...
Evrysdi® (risdiplam) is the first and only oral, non-invasive treatment for spinal muscular atrophy (SMA) in pediatric and adult patients. Please see Important...
spinal muscular atrophyrisdiplamapprovedpediatric